No abstract

SummaryIn mice, natural resistance or susceptibility to infection with intracellular parasites is determined by a locus or group of loci on chromosome 1, designated Bcg, Lsh, and Ity, which controls early microbial replication in reticuloendothelial organs. We have identified by positional cloning a candidate gene for Beg, Nrampl, which codes for a novel macrophage-specific membrane transport protein. We have created a mouse mutant bearing a null allele at Nrampl, and we have analyzed the effect of such a mutation on natural resistance to infection. Targeted disruption of Nrampl has pleiotropic effects on natural resistance to infection with intracellular parasites, as it eliminated resistance to Mycobacterium boris, Leishmania donovani, and lethal Salmonella typhimurium infection, establishing that Nrampl, Bcg, Lsh, and It), are the same locus. Comparing the profiles of parasite replication in control and Nrampl -/-mice indicated that the NramplAse 169 allele of Beg s inbred strains is a null allele, pointing to a critical role of this residue in the mechanism of action of the protein. Despite their inability to control parasite growth in the early nonimmune phase of the infection, Nrampl -/-mutants can overcome the infection in the late immune phase, suggesting that Nrampl plays a key role only in the early part of the macrophage-parasite interaction and may function by a cytocidal or cytostatic mechanism distinct from those expressed by activated macrophages.

Viral respiratory tract infections are the main causative agents of the onset of infection-induced asthma and asthma exacerbations that remain mechanistically unexplained. Here we found that deficiency in signaling via type I interferon receptor led to deregulated activation of group 2 innate lymphoid cells (ILC2 cells) and infection-associated type 2 immunopathology. Type I interferons directly and negatively regulated mouse and human ILC2 cells in a manner dependent on the transcriptional activator ISGF3 that led to altered cytokine production, cell proliferation and increased cell death. In addition, interferon-γ (IFN-γ) and interleukin 27 (IL-27) altered ILC2 function dependent on the transcription factor STAT1. These results demonstrate that type I and type II interferons, together with IL-27, regulate ILC2 cells to restrict type 2 immunopathology.

In patients with an apnea-hypopnea index of 30 or greater and no subjective daytime sleepiness, CPAP does not modify quality of life, objective sleepiness, vigilance, attention, memory, information processing, visuomotor coordination, or arterial blood pressure. Treatment with CPAP is therefore not indicated in nonsleepy patients with a pathologic apnea-hypopnea index.